GlassScriptPhysician profile
William Stephen Johnson
NPI 1386797157
$2,227.21
in general payments reported to CMS, 2019-2025
18 companies · $333 in 2025
The $333 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $112 · 2021: $402 · 2022: $337 · 2023: $437 · 2024: $359 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $506.84 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $255.39 | 2019-2025 | Bexsero, Pediarix |
| Pfizer INC. | $225.21 | 2019-2025 | |
| Tris Pharma INC | $191.32 | 2019-2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $186.06 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $164.19 | 2021-2023 | Qelbree |
| Adlon Therapeutics L.P. | $158.04 | 2020-2021 | |
| Sanofi Pasteur INC. | $129.30 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $96.29 | 2019-2023 | Jornay Pm |
| Kaleo, INC. | $81.74 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.47 | 2019-2021 | |
| Seqirus USA INC | $52.43 | 2021-2023 | Flucelvax Quadrivalent |
| Abbvie INC. | $26.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $22.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.34 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18.11 | 2025 | Id Now Instrument |
| Rhodes Pharmaceuticals L.P. | $17.77 | 2019 | |
| Cipher Pharmaceuticals US LLC | $15.34 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.